Tatva Chintan Pharma Chem Limited (TATVA) Earnings Call Transcripts

Tatva Chintan Pharma Chem Limited's Latest Earnings Call - Q4 FY2026

In Q4 FY '26, Tatva Chintan Pharma Chem Limited reported a strong operating revenue of INR 1,341 million, reflecting a 24% year-on-year growth. The EBITDA surged to INR 281 million, a remarkable increase of 214% year-on-year, driven by an improved product mix and operational efficiencies. Management maintained its revenue growth guidance for FY '27 at 20-25%, signaling confidence in sustained demand across key segments despite geopolitical challenges affecting raw material costs.

Reported metrics

Guidance from management

Management maintained revenue growth guidance of 20-25% for FY '27, indicating confidence in demand stability across segments despite geopolitical challenges affecting raw material costs.

What management said

Yes. So the -- actually, this has -- the guidance has already been given in our previous calls. We have already maintained that we will be growing the revenue by around and EBITDA should be in the range of somewhere around 20% to 22% on a very realistic basis. So we will lead to that.

Not actually because -- so the crisis are going up due to the geopolitical situation and other things. But gradually, it is being absorbed by our customers. Our customers are operating although they are not being as of at 100% level, but probably, we believe that it will gradually be absorbed and we don't intend to change anything on our guidance in that matter.

What analysts pressed on

Analysts expressed concerns regarding the impact of rising raw material costs on margins and the sustainability of growth in the face of geopolitical uncertainties. There were questions about the visibility of orders in the Electrolyte segment and the execution timeline for new projects.

Main topics on the call

• Strong Revenue Growth — The company achieved operating revenue of INR 1,341 million, a 24% increase year-on-year. Management noted, "We have been observing a gradual pickup in momentum in business activity across the segments," indicating a pos...
• Significant EBITDA Improvement — EBITDA for the quarter reached INR 281 million, up 214% year-on-year. This improvement was attributed to a "better product mix and improved operating leverage," showcasing effective cost management.
• Electrolyte Segment Growth — The Electrolyte segment reported exceptional growth of 865% quarter-on-quarter, with management stating, "We expect this trajectory to strongly strengthen during the current year," highlighting its strategic importance.
• Pharma and Agro Intermediates Outlook — Management indicated that the Pharma segment is set to contribute INR 70-75 million in revenue in FY '27, with commercial production beginning for new products. This reflects a positive shift in the segment's growth traj...

Read the full Tatva Chintan Pharma Chem Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 12 Tatva Chintan Pharma Chem Limited earnings call transcripts on record, spanning January 24, 2023 to July 17, 2026. Based on this history, Tatva Chintan Pharma Chem Limited reports semi-annually. The most recent call on file is dated July 17, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

TATVA

Exchange

NSEI

Country

IN

Sector

Materials

Industry

Chemicals

Calls on record

12

First call

January 24, 2023

Most recent

July 17, 2026

Reporting cadence

semi-annually